FDFangyuan Dou

Fangyuan Dou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fangyuan Dou has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Dongfeng Niu

    Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China

    1 shared publication
  • Dongmei Lin

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China

    1 shared publication
  • Kennichi Kakudo

    Department of Pathology, Nara Hospital, Kindai University Faculty of Medicine, Ikoma-city, Nara, 630-0293, Japan

    1 shared publication
  • Ling Jia

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, China

    1 shared publication
  • Qiang Kang

    Beijing Cancer Hospital

    1 shared publication
  • Qin Feng

    Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital &Institute, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma

    by Yanhua Bai, Dongfeng Niu, Xiaozheng Huang, Ling Jia, Qiang Kang, Fangyuan Dou, Xinqiang Ji, Weicheng Xue, Yiqiang Liu, Zhongwu Li, et al.

    Immune checkpoint blockade targeting PD-1/PD-L1 has shown efficacy in several types of cancers. However, the correlation between PD-L1/PD-1 expression and the specific clinicopathological features in papillary thyroid carcinoma (PTC) has not been investigated. We examined the immunohistochemical expression of PD-L1, PD-1, and BRAF V600E on whole-tissue sections from 126 cases of primary PTC more than 1 cm in size. The correlation between the PD-L1/PD-1 expression and the clinicopathological features was evaluated. PD-L1 was positively expressed in 53.2% PTCs, and its expression was positively correlated with rich tumor-infiltrating lymphocytes (TILs), background chronic lymphocytic thyroiditis (CLT), female gender, absence of psammoma bodies, and PD-1 expression. Among these parameters, rich TILs, female gender, and absence of psammoma bodies were independent factors affecting PD-L1 expression on the multivariate logistic regression analysis. PD-1 expression was detected in the TILs and was positively correlated with rich TILs, background CLT, and absence of stromal calcification. Lack of stromal calcification was an independent factor affecting PD-1 expression. Neither PD-L1 nor PD-1 expression showed significant correlation with BRAF V600E expression. Our results show that the distinctive pathological features of PTCs, including TILs, background CLT, female gender, psammoma bodies, and stromal calcification, are useful parameters for predicting PD-L1 or PD-1 expression.